Brexanolone: An informative study

Authors

  • Sumit Kumar Rai nill Author
  • Dr. Keerthana Kuma nill Author
  • Shefali Deo Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India Author
  • Dr. Khayati Moudgil Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India Author

DOI:

https://doi.org/10.61841/nx3nae19

Keywords:

Depression, Postpartum, Brexanolone, chronic

Abstract

The birth of a baby will cause the joy, satisfaction, fear and anxiety to mix up with powerful emotions. Yet it may also lead to something that you do not foresee-depression. Upon childbirth most new mothers experience "baby blues," which usually include mood swings, crying kinds, anxiety, and sleeping difficulty. Usually, baby blues start within a two- to three-day span and can last up to two weeks. However, some new moms experience more serious, chronic depression called postpartum depression. Our aim is to include an Informative Overview of Brexanolone (Zulresso) in postpartum depression (PPD), a new antidepressant with a new mechanism of action.

 

Downloads

Download data is not yet available.

References

1. Mauthner NS. Re-assessing the importance and role of the marital relationship in postnatal depression: Methodological and theoretical implications. Journal of Reprod Infant Psychol. 1998;16(2–3):157–75.

2. Fishel AH. Mental health disorders and substance abuse. Maternity & women’s health care; 2004:960–82.

3. Schmied V, Johnson M, Naidoo N, Austin MP, Matthey S, Kemp L, Mills A, Meade T, Yeo A. Maternal mental health in Australia and New Zealand: a review of longitudinal studies. Women Birth. 2013 Sep;26(3):167-78. [PubMed]

4. Shidhaye R, Mendenhall E, Sumathipala K, Sumathipala A, Patel V. Association of somatoform disorders with anxiety and depression in women in low and middle income countries: a systematic review. Int Rev Psychiatry. 2013 Feb;25(1):65-76. [PMC free article] [PubMed]

5. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005 Nov;106(5 Pt 1):1071-

83. [PubMed]

6. Johannsen BM, Larsen JT, Laursen TM, Bergink V, Meltzer-Brody S, Munk-Olsen T. All-Cause Mortality in Women With Severe Postpartum Psychiatric Disorders. Am J Psychiatry. 2016 Jun 01;173(6):635-42. [PMC free article] [PubMed]

7. Noorlander Y, Bergink V, van den Berg MP. Perceived and observed mother-child interaction at time of hospitalization and release in postpartum depression and psychosis. Arch Womens Ment Health. 2008;11(1):49-56. [PubMed]

8. Luisi S, Petraglia F, Benedetto C, Nappi RE, Bernardi F, Fadalti M, Reis FM, Luisi M, Genazzani AR. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J. Clin. Endocrinol. Metab. 2000 Jul;85(7):2429-33. [PubMed]

9. Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 1992 Mar;6(6):2311-22. [PubMed]

10. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci. 2005 Mar;6(3):215-29. [PubMed]

11. Tsutsui K, Haraguchi S. Biosynthesis and biological action of pineal allopregnanolone. Frontiers in Cellular Neuroscience. 2014;8.

12. Hutcherson

Downloads

Published

31.10.2020

Issue

Vol. 24 No. 8 (2020): 24 (8) 2020

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

Rai, S. K., Kuma, K., Deo, S., & Moudgil, D. K. (2020). Brexanolone: An informative study. International Journal of Psychosocial Rehabilitation, 24(8), 6658-6662. https://doi.org/10.61841/nx3nae19